Jacqueline C Barrientos Selected Research

idelalisib

1/2021	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
10/2020	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial.
11/2019	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
1/2019	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
6/2018	Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
1/2017	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
12/2016	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
9/2016	Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
1/2016	Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
1/2015	Management of adverse events associated with idelalisib treatment: expert panel opinion.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacqueline C Barrientos Research Topics

Disease

32	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 03/2014
10	Neoplasms (Cancer) 01/2021 - 08/2013
10	Diarrhea 01/2021 - 07/2014
6	Pneumonia (Pneumonitis) 01/2021 - 01/2015
5	Colitis 01/2021 - 01/2015
5	Hemorrhage 01/2021 - 08/2015
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 08/2013
4	Neutropenia 01/2021 - 12/2016
4	Infections 01/2021 - 08/2015
3	Atrial Fibrillation 01/2020 - 12/2018
3	Hypertension (High Blood Pressure) 12/2019 - 12/2018
3	Lymphocytosis 01/2019 - 06/2014
3	Fatigue 01/2019 - 07/2014
2	COVID-19 03/2022 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2017
2	Lymphoma (Lymphomas) 11/2020 - 01/2017
2	Disease Progression 01/2019 - 01/2017
2	Fever (Fevers) 01/2017 - 07/2014
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2015 - 08/2013
1	Leukocytosis (Pleocytosis) 01/2021
1	Arthralgia (Joint Pain) 01/2020
1	Leukemia 11/2019
1	Chronic Disease (Chronic Diseases) 12/2018
1	Tumor Lysis Syndrome 12/2018
1	Weight Loss (Weight Reduction) 12/2018
1	Sudden Death 01/2017
1	Lymphadenopathy 01/2017
1	Febrile Neutropenia 01/2017
1	Exanthema (Rash) 12/2016
1	Intestinal Perforation 01/2016
1	Residual Neoplasm 10/2015
1	Frailty 10/2015
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 08/2015
1	Hematologic Neoplasms (Hematological Malignancy) 01/2015
1	Lymphoid Leukemia 07/2014
1	Nausea 07/2014
1	Chromosome Aberrations (Chromosome Abnormalities) 07/2014
1	Cough 07/2014

Drug/Important Bio-Agent (IBA)

21	ibrutinibIBA 01/2021 - 08/2013
13	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 08/2013
11	idelalisibIBA 01/2021 - 03/2014
10	Rituximab (Mabthera)FDA Link 11/2019 - 03/2014
6	Bendamustine Hydrochloride FDA Link 11/2019 - 05/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 10/2015
2	acalabrutinibIBA 01/2021 - 01/2016
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2019 - 07/2014
2	Transaminases (Aminotransferases)IBA 01/2019 - 12/2016
2	ofatumumab FDA Link 12/2018 - 07/2014
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2016 - 01/2015
1	mRNA VaccinesIBA 03/2022
1	Messenger RNA (mRNA)IBA 03/2022
1	VaccinesIBA 03/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	duvelisibIBA 01/2021
1	umbralisibIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 11/2020
1	Alemtuzumab (Campath)FDA Link 03/2016
1	Monoclonal AntibodiesIBA 10/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2015
1	fludarabineIBA 05/2015
1	SteroidsIBA 01/2015
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2015
1	NucleotidesIBA 07/2014
1	Lenalidomide (CC 5013)FDA Link 07/2014

Therapy/Procedure

20	Therapeutics 01/2021 - 07/2014
3	Drug Therapy (Chemotherapy) 11/2019 - 03/2014
1	Drug Tapering 01/2019
1	Transplantation 12/2016
1	Cell Transplantation 12/2016